Maravai LifeSciences
MRVI
196 hedge funds and large institutions have $4.77B invested in Maravai LifeSciences in 2021 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 74 increasing their positions, 34 reducing their positions, and 27 closing their positions.
196% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 27
118% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 34
36% more funds holding
Funds holding: 144 → 196 (+52)
36% more capital invested
Capital invested by funds: $3.51B → $4.77B (+$1.27B)
26% more call options, than puts
Call options by funds: $4.18M | Put options by funds: $3.31M
1.79% less ownership
Funds ownership: 101.8% → 100% (-1.8%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Select Equity Group
New York
|
+$126M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$116M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$114M |
| 4 |
OCBV
Ownership Capital B.V.
Amsterdam,
Netherlands
|
+$90.3M |
| 5 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$67.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
GTCR LLC
Chicago,
Illinois
|
-$118M |
| 2 |
Lazard Asset Management
New York
|
-$63.7M |
| 3 |
HM
HealthCor Management
New York
|
-$44.8M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$38.3M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$26M |
MRVI Hedge Fund Activity: Q2 2021 in Review
196 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2021, worth a combined $4.77B — up 36% from $3.51B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new MRVI positions and 27 closed out — a net gain of 53 holders — while 74 added to existing stakes and 34 trimmed.
The largest buyer was Select Equity Group, adding an estimated $126M. The largest seller was GTCR LLC, cutting an estimated $118M.
- 196 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2021, up from 144 in Q1 2021.
- Funds reported $4.77B of Maravai LifeSciences stock for Q2 2021, up 36% quarter-over-quarter.
- 80 funds opened new Maravai LifeSciences positions in Q2 2021 and 27 closed out, a net change of +53 holders.
- The largest Maravai LifeSciences buyer in Q2 2021 was Select Equity Group, an estimated $126M added.
- The largest Maravai LifeSciences seller in Q2 2021 was GTCR LLC, an estimated $118M sold.
Based on aggregated 13F filings for Q2 2021.